# US 6,730,313 B2 · Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,313 B2
- Document ID: US6730313B2
- Status: Granted
- Kind: B2
- Application number: 09/771,480
- Filed: 2001-01-25
- Published: 2002-02-28
- Granted: 2004-05-04
- Earliest claimed: 2000-01-25
- Assignees: Edwards Lifesciences Corporation
- Inventors: Michael N. Helmus; Crystal M. Cunanan; Patrice Tremble
- Web page: https://patentgrep.com/patent/US6730313B2

## CPC

- A61L 27/52: Hydrogels or hydrocolloids
- A61L 27/225: {Fibrin; Fibrinogen}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 31/04: Macromolecular materials
- A61L 31/145: {Hydrogels or hydrocolloids}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/602: Type of release, e.g. controlled, sustained, slow
- A61L 2300/606: Coatings
- A61L 2300/622: Microcapsules
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides methods for treating injuries to one or more internal structures of a subject by administering a drug delivery vehicle to an external surface of the injured structure. The drug delivery vehicle substantially adheres to the site of administration and provides for the release of a bioactive agent that reduces or prevents further injury to the internal structure by disease processes, such as hyperplasia.

## Claims

### Claim 1

A method of preventing or reducing intimal hyperplasia at a site of insult to an internal structure in a subject, said method comprising:
contacting an exterior surface of said internal structure contiguous with said site of insult, with a drug delivery vehicle comprising an intimal hyperplasia preventing agent, wherein said drug delivery vehicle is substantially flowable during application to said exterior surface and substantially adheres to said exterior surface of said internal structure; and
said drug delivery vehicle releasing said intimal hyperplasia preventing agent in a time dependent manner, said releasing occurring in an amount effective to prevent or reduce said intimal hyperplasia.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said internal structure is a structure having a substantially circular cross-section.

### Claim 3 (depends on 2)

The method according to claim 2, wherein said internal structure is a member selected from vascular system component, an intestinal system component, a urinary system component and combinations thereof.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said insult is an injury arising from a surgical procedure.

### Claim 5 (depends on 4)

The method according to claim 4, wherein said internal structure is a vascular structure and said surgical procedure is a member selected from the group consisting of angioplasty, vascular reconstructive surgery, heart valve replacement, heart transplantation and combinations thereof.

### Claim 6 (depends on 4)

The method according to claim 4, wherein said surgical procedure comprises placing a prosthesis at said site of insult on said internal structure.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said prosthesis comprises a member selected from a stent, a graft, a valve and combinations thereof at said site of insult on said internal structure.

### Claim 8 (depends on 6)

The method according to claim 6, wherein said exterior surface of said vascular structure contacted with said drug delivery vehicle comprises both said prosthesis and said site of insult.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said site of insult comprises an anastomosis.

### Claim 10 (depends on 9)

The method according to claim 9, wherein said exterior surface of said vascular structure contacted with said drug delivery vehicle comprises said anastomosis.

### Claim 11 (depends on 1)

The method according to claim 1, wherein said intimal hyperplasia preventing agent is a member selected from antithrombotics, antiinflammatories, corticosteroids, antimicrotubule agents, antisense oligonucleotides, antineoplaastics, antioxidants, antiplatelets, calcium channel blockers, converting enzyme inhibitors, cytokine inhibitors, growth factors, growth factor inhibitors, growth factor sequestering agents, fibrosis inhibitors, immunosuppressives, tissue factor inhibitor, smooth muscle inhibitors, sulfated proteoglycans, superoxide dismutase mimics, NO, NO precursors and combinations thereof.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said antithrombotic is a member selected from heparin, heparin derivatives hirudin, hirudin derivatives and combinations thereof.

### Claim 13 (depends on 11)

The method according to claim 11, wherein said corticosteroid is dexamethasone, dexamethasone derivatives and combinations thereof.

### Claim 14 (depends on 11)

The method according to claim 11, wherein said antimicrotubule agent is a member selected from taxane, taxane derivatives and combinations thereof.

### Claim 15 (depends on 11)

The method according to claim 11, wherein said antiplatelet agent or said fibrosis inhibitor is an inhibitor of collagen synthesis.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said inhibitor of collagen synthesis is selected from halofuginore, halofuginore derivatives, GpIIbIIIa and combinations thereof.

### Claim 17 (depends on 1)

The method according to claim 1, wherein said drug delivery vehicle is a member selected from bioerodable vehicles, hydrogel vehicles, thermoreversible vehicles, bioresorbable vehicles and combinations thereof.

### Claim 18 (depends on 17)

The method according to claim 17, wherein said vehicle comprises a member selected from gels, foams, suspensions, microcapsules, solid polymeric supports and fibrous structures.

### Claim 19 (depends on 17)

The method according to claim 17, wherein said vehicle comprises a bioresorbable component.

### Claim 20 (depends on 19)

The method according to claim 19, wherein said bioresorbable component is insoluble in water.

### Claim 21 (depends on 20)

The method according to claim 20, wherein said bioresorbable component is hydrophobic.

### Claim 22 (depends on 19)

The method according to claim 19, wherein said bioresorbable component is hydrolytically and/or enzymatically cleavable.

### Claim 23 (depends on 19)

The method according to claim 19, wherein said bioresorbable component is selected from the group consisting of poly(esters), poly(hydroxy acids), poly(lactones), poly(amides), poly(ester-amides), poly (amino acids), poly(anhydrides), poly(orthoesters), poly(carbonates), poly(phosphazines), poly(phosphoesters), poly(thioesters), polysaccharides and mixtures thereof.

### Claim 24 (depends on 23)

The method according to claim 23, wherein said bioresorbable component is a poly(hydroxy) acid.

### Claim 25 (depends on 24)

The method according to claim 24, wherein said poly(hydroxy) acid comprises a material selected from the group consisting of poly(lactic) acid, poly(glycolic) acid, poly(caproic) acid, poly(butyric) acid, poly(valeric) acid and copolymers and mixtures thereof.

### Claim 26 (depends on 17)

The method according to claim 17, wherein said vehicle forms a member selected from excretable fragments, metabolizable fragments and combinations thereof.

### Claim 27 (depends on 18)

The method according to claim 18, wherein said gel is a thermoreversible gel.

### Claim 28 (depends on 27)

The method according to claim 27, wherein said gel comprises a member selected from pluronics, fibrin sealants, albumin, collagen, gelatin, hydroxypropylmethylcellulose, polyethylene oxide, hyalouronic acid, polysaccharides and combinations thereof.

### Claim 29 (depends on 28)

The method according to claim 28, wherein said gel comprises a member selected from polyurethane hydrogel and polyurethane-urea hydrogel.

### Claim 30 (depends on 17)

The method according to claim 17, wherein said drug delivery vehicle comprises a member selected from fibrin, fibronectin, thrombin and combinations thereof.

### Claim 31

A method of preventing or reducing intimal hyperplasia at a site of insult to a vascular structure in a subject, wherein said insult is a member selected from the group consisting of angioplasty, vascular reconstructive surgery and combinations thereof, said method comprising:
contacting an exterior surface of said vascular structure contiguous with said site of insult, with a drug delivery vehicle comprising an intimal hyperplasia preventing agent, wherein said drug delivery vehicle is substantially flowable during application to said exterior surface and substantially adheres to said exterior surface of said internal structure; and
said drug delivery vehicle releases said intimal hyperplasia preventing agent in a time dependent manner, said release occurring in an amount effective to prevent or reduce said intimal hyperplasia.

### Claim 32 (depends on 31)

The method according to claim 31, wherein said vascular reconstructive surgery comprises placing a member selected from a stent, a graft and combinations thereof at the site of insult.

### Claim 33 (depends on 32)

The method according to claim 32, wherein said exterior surface of said vascular structure contacted with said drug delivery vehicle comprises a member selected from both said stent and said site of insult, both said graft and said site of insult and combinations thereof.

### Claim 34 (depends on 31)

The method according to claim 31, wherein said site of insult comprises an anastomosis.

### Claim 35 (depends on 34)

The method according to claim 34, wherein said exterior surface of said exterior surface of said vascular structure contacted with said drug delivery vehicle comprises said anastomosis.

### Claim 36 (depends on 31)

The method according to claim 31, wherein said intimal hyperplasia preventing agent is a member selected from antithrombotics, antiinflammatories, corticosteroids, antimicrotubule agents, antisense oligonucleotides, antineoplaastics, antioxidants, antiplatelets, calcium channel blockers, converting enzyme inhibitors, cytokine inhibitors, growth factors, growth factor inhibitors, growth factor sequestering agents, fibrosis inhibitors, immunosuppressives, tissue factor inhibitor, smooth muscle inhibitors, sulfated proteoglycans, superoxide dismutase mimics, NO, NO precursors and combinations thereof.

### Claim 37 (depends on 36)

The method according to claim 36, wherein said antithrombotic is a member selected from heparin, heparin derivatives hirudin, hirudin derivatives and combinations thereof.

### Claim 38 (depends on 36)

The method according to claim 36, wherein said corticosteroid is dexamethasone, dexamethasone derivatives and combinations thereof.

### Claim 39 (depends on 36)

The method according to claim 36, wherein said antimicrotubule agent is a member selected from taxane, taxane derivatives and combinations thereof.

### Claim 40 (depends on 36)

The method according to claim 36, wherein said antiplatelet agent or said fibrosis inhibitor is an inhibitor of collagen synthesis.

### Claim 41 (depends on 40)

The method according to claim 40, wherein said inhibitor of collagen synthesis is selected from halofuginore, halofuginore derivatives, GpIIbIIIa and combinations thereof.

### Claim 42 (depends on 31)

The method according to claim 31, wherein said drug delivery vehicle is a member selected from bioerodable vehicles, hydrogel vehicles, thermoreversible vehicles, bioresorbable vehicles and combinations thereof.

### Claim 43 (depends on 42)

The method according to claim 42, wherein said drug delivery vehicle comprises a member selected from fibrin, fibronectin, thrombin and combinations thereof.

### Claim 44

A method of treating a disease state of an internal structure in a subject, said method comprising:
surgically treating said disease state, thereby creating a surgical site; and
contacting an exterior surface of said internal structure contiguous with said surgical site, with a drug delivery vehicle comprising an intimal hyperplasia preventing agent, wherein said drug delivery vehicle is substantially flowable during application to said exterior surface and substantially adheres to said exterior surface of said internal structure; and
said drug delivery vehicle releases said intimal hyperplasia preventing agent in a time dependent manner, said release occurring in an amount effective to prevent or reduce said intimal hyperplasia.

### Claim 45 (depends on 44)

The method according to claim 44, wherein said internal structure has a substantially circular cross-section.

### Claim 46 (depends on 45)

The method according to claim 45, wherein said structure is a member selected from vascular system component, an intestinal system component, a urinary system component and combinations thereof.

### Claim 47 (depends on 44)

The method according to claim 44, wherein said internal structure is a vascular structure and said surgical procedure is a member selected from the group consisting of angioplasty, vascular reconstructive surgery and combinations thereof.

### Claim 48 (depends on 47)

The method according to claim 47, wherein said vascular reconstructive surgery comprises placing a prosthesis at said surgical site.

### Claim 49 (depends on 48)

The method according to claim 48, wherein said prosthesis comprises a member selected from a stent, a graft, a valve and combinations thereof at said site of insult on said internal structure.

### Claim 50 (depends on 48)

The method according to claim 48, wherein said exterior surface of said vascular structure contacted with said drug delivery vehicle comprises a member selected from both said stent and said site of insult, both said graft and said site of insult and combinations thereof.

### Claim 51 (depends on 44)

The method according to claim 44, wherein said site of insult comprises an anastomosis.

### Claim 52 (depends on 51)

The method according to claim 51, wherein said exterior surface of said vascular structure contacted with said drug delivery vehicle comprises said anastomosis.

### Claim 53 (depends on 44)

The method according to claim 44, wherein said intimal hyperplasia preventing agent is a member selected from antithrombotics, antiinflammatories, corticosteroids, antimicrotubule agents, antisense oligonucleotides, antineoplaastics, antioxidants, antiplatelets, calcium channel blockers, converting enzyme growth factor sequestering agents, cytokine inhibitors, growth factors, growth factor inhibitors, fibrosis inhibitors, immunosuppressives, tissue factor inhibitor, smooth muscle inhibitors, sulfated proteoglycans, superoxide dismutase mimics, NO, NO precursors and combinations thereof.

### Claim 54 (depends on 53)

The method according to claim 53, wherein said antithrombotic is a member selected from heparin, heparin derivatives hirudin, hirudin derivatives and combinations thereof.

### Claim 55 (depends on 53)

The method according to claim 53, wherein said corticosteroid is dexamethasone, dexamethasone derivatives and combinations thereof.

### Claim 56 (depends on 53)

The method according to claim 53, wherein said antimicrotubule agent is a member selected from taxane, taxane derivatives and combinations thereof.

### Claim 57 (depends on 53)

The method according to claim 53, wherein said antiplatelet agent or said fibrosis inhibitor is an inhibitor of collagen synthesis.

### Claim 58 (depends on 57)

The method according to claim 57, wherein said inhibitor of collagen synthesis is selected from halofuginore, halofuginore derivatives, GpIIbIIIa and combinations thereof.

### Claim 59 (depends on 44)

The method according to claim 44, wherein said drug delivery vehicle is a member selected from bioerodable vehicles, hydrogel vehicles, thermoreversible vehicles, bioresorbable vehicles and combinations thereof.

### Claim 60 (depends on 59)

The method according to claim 59, wherein said drug delivery vehicle comprises a member selected from fibrin, fibronectin, thrombin and combinations thereof.

### Claim 61 (depends on 44)

The method according to claim 44, wherein said disease is a member selected from peripheral vascular disease, coronary artery disease, cardiac disease, hyperplastic disease.
